Prognostic factors for survival in metastatic breast cancer by hormone receptor status

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 503-511

  Kwast, A B G ^a,b   Voogd, A C ^a,c   Menke Pluijmers, M B E ^d   Linn, S C ^e   Sonke, G S ^a,e   Kiemeney, L A ^b   Siesling, S ^a,f  

^a Department of Cancer Registry and Research   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Hormone receptor status; Metastatic breast cancer; Prognostic factors; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DUTCH; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME; BREAST TUMOR; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE;

EID: 84901660437     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2964-0     Document Type: Article

References (21)

1. Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742-1750 (Pubitemid 41437440)
2. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44-52 (Pubitemid 37553538)
3. Insa A, Lluch A, Prosper F et al (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients. Breast Cancer Res Treat 56:67-78 (Pubitemid 29435816)
4. Largillier R, Ferrero JM, Doyen J et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19:2012-2019
5. Planchat E, Durando X, Abrial C et al (2011) Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest 29:635-643
6. Chang J, Clark GM, Allred DC et al (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545-553 (Pubitemid 36125831)
7. Clark GM, Sledge GW Jr, Osborne CK et al (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61 (Pubitemid 17007856)
8. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401-2408 (Pubitemid 28309034)
9. Fritz A, Percy C, Jack A, Shanmugarathnam K, Sobin L, Parkin DM. International Classification of Diseases for Oncology. Therd ed. 3rd edition ed. Geneva: WHO; 2000
10. Sobin L, Wittekind C (2008) TNM Atlas, 6th edn. UICC, New York
11. Blanco G, Holli K, Heikkinen M et al (1990) Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62:142-146 (Pubitemid 20226464)
12. Guarneri V, Bengala C, Orlandini C et al (2004) HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplant 34:413-417 (Pubitemid 39232370)
13. Manders K, van de Poll-Franse LV, Creemers GJ et al (2006) Clinical management of women with metastatic breast cancer: A descriptive study according to age group. BMC Cancer 6:179 (Pubitemid 44203873)
14. Wei S, Li Y, Siegal GP et al (2011) Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol 15:79-83
15. Kwast AB, Groothuis-Oudshoorn KC, Grandjean I et al (2012) Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Res Treat 135:271-280
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)
17. Kleeberg UR, Fink M, Tessen HW et al (2013) Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer: own findings and review of the literature. Onkologie 36:348-356
18. Pagani O, Senkus E, Wood W et al (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102:456-463
19. Thompson AM, Jordan LB, Quinlan P et al (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12:R92
20. Bogina G, Bortesi L, Marconi M et al (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459:1-10
21. Hoefnagel LD, van de Vijver M, van Slooten HJ et al (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12:R75